Wishing you a very Happy Birthday | Dr. Emilio Jirillo




Dr. Emilio Jirillo serves as the Editor-in-Chief of the Journal: Endocrine, Metabolic & Immune Disorders – Drug Targets


Department of Basic Medical Sciences Neuroscience and Sensory Organs
University of Bari “Aldo Moro”

World Aids Day, 2019!


Bentham Science Publish articles related to WORLD AIDS DAY in its subscription based journals including: 


Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Volume 5, Issue 1, February, 2006 – Volume 18, Issue 2, September, 2019

Current HIV Research
Volume 1, Issue 1, January, 2003 – Volume 17, Issue 5, September, 2019

Current Immunology Reviews
Volume 1, Issue 1, January, 2005 – Volume 15, Issue 2, August, 2019


Endocrine, Metabolic & Immune Disorders – Drug Targets
Volume 6, Issue 1, March, 2006 – Volume 19, Issue 8, December, 2019

Recent Patents on Inflammation & Allergy Drug Discovery
Volume 1, Issue 1, February, 2007 – Volume 13, Issue 2, October, 2019

For eBooks, Please find the link HERE consisting of all the relevant eBooks and avail 30% DISCOUNT OFFER on related Books!



Today is World Obesity Day, 2019!

Bentham Science publishes articles related to World Obesity Day in its Subscription based journals including:

  1. Current Diabetes Reviews 
  2. Endocrine, Metabolic & Immune Disorders – Drug Targets

For eBooks, please find the link here consisting of all relevant eBooks and avail our 30% DISCOUNT OFFER on related eBooks!




World Obesity Day

World Obesity Day was launched in 2015 to stimulate and support practical solutions to help people achieve and maintain a healthy weight, and to reverse the obesity crisis. The aim is to increase awareness, encourage advocacy, improve policies, and share experiences.

Aims & Scope – Endocrine, Metabolic & Immune Disorders – Drug Targets

Aims & Scope:

This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.




For more details, please visit: https://benthamscience.com/journals/endocrine-metabolic-and-immune-disorders-drug-targets/aims-scope/#top

Most Accessed Articles – The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies

Author(s): Gholamreza Azizi, Yasser Bagheri, Marzieh Tavakol, Forough Askarimoghaddam, Kumars Porrostami, Hosein Rafiemanesh, Reza Yazdani, Fatemeh Kiaee, Sima Habibi, Kosar Abouhamzeh, Hamed Mohammadi, Mostafa Qorbani, Hassan Abolhassani, Asghar Aghamohammadi*.

Graphical Abstract:



Background: Primary antibody deficiency (PAD) comprises a range of diseases from early to late terminal B cells defects and is associated with the various clinical complications.

Methods: A total of 461 patients (311 males and 150 females) with PADs enrolled in the retrospective cohort study and for all patients’ demographic information, clinical records and laboratory data were collected to investigate clinical complications.

Results: The most prevalent first presentations of immunodeficiency were respiratory tract infections in 63.5% and chronic diarrhea in 17.2%. Common variable immune deficiency (CVID) patients had a higher diagnostic delay than class switching defect (CSD), and agammaglobulinemia. Among the noninfectious complications, autoimmunity (26.2%), and splenomegaly (23.4%) were the most common. Lymphadenopathy was higher in CSD patients than other PADs, while splenomegaly, hepatomegaly, autoimmunity and bronchiectasis were more common in CVID patients than others. Atopic manifestations were mostly recorded in patients with selective IgA deficiency. Malignancy was only reported in 5.8% of patients with CVID. There was a higher prevalence of autoimmune manifestations in CVID comparing to other PADs.

Conclusion: PADs are relatively rare diseases and these patients have a variety of first clinical manifestations, such as diverse infections, autoimmunity, lymphoproliferation, allergy, enteropathy and malignancy. Practitioner’s awareness about the heterogeneous presentations of PAD disorders is poor, therefore patients often are lately diagnosed, and they are complicated with several clinical complications before the certain diagnosis.


For more details, please visit: http://www.eurekaselect.com/161253

Open Access Articles – Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis

Author(s): Velichka Pavlova*, Elena Filipova, Katya Uzunova, Krassimir Kalinov, Toni Vekov.

Graphical Abstract:


Introduction: Thiazolidinediones are a group of synthetic medications used in type 2 diabetes treatment. Among available thiazolidinediones, pioglitazone is gaining increased attention due to its lower cardiovascular risk in type 2 diabetes mellitus sufferers and seems a promising future therapy. Accumulating evidence suggests that diabetic patients may exert bone fractures due to such treatments. Simultaneously, the female population is thought to be at greater risk. Still, the safety outcomes of pioglitazone treatment especially in terms of fractures are questionable and need to be clarified.

Methods: We searched MEDLINE, Scopus, PsyInfo, eLIBRARY.ru electronic databases and clinical trial registries for studies reporting an association between pioglitazone and bone fractures in type 2 diabetes mellitus patients published before Feb 15, 2016. Among 1536 sources that were initially identified, six studies including 3172 patients proved relevant for further analysis.

Result: Pooled analysis of the included studies demonstrated that after treatment with pioglitazone patients with type 2 diabetes mellitus had no significant increase in fracture risk [odds ratio (OR): 1.18, 95% confidence interval (CI): 0.82 to 1.71, p=0.38] compared to other antidiabetic drugs or placebo. Additionally, no association was found between the risk of fractures and pioglitazone therapy duration. The gender of the patients involved was not relevant to the risk of fractures, too.

Conclusion: Pioglitazone treatment in diabetic patients does not increase the incidence of bone fractures. Moreover, there is no significant association between patients’ fractures, their gender and the period of exposure to pioglitazone. Additional longitudinal studies need to be undertaken to obtain more detailed information on bone fragility and pioglitazone therapy.



For more details, please visit: http://www.eurekaselect.com/161486


Current Protein & Peptide Science Volume 19, Issue 4

Combinatorial Chemistry & High Throughput Screening Volume 20, Issue 10

Current Pharmaceutical Biotechnology Volume 18, Issue 11

Endocrine, Metabolic & Immune Disorders – Drug Targets Volume 18, Issue 2

Mini-Reviews in Medicinal Chemistry Volume 18, Issue 5

Current Drug Delivery Volume 15, Issue 2



Dr.Emilio Jirillo.jpg


EDITOR-IN-CHIEF: Endocrine, Metabolic & Immune Disorders – Drug Targets & Clinical Immunology, Endocrine & Metabolic Drugs

Department of Basic Medical Sciences Neuroscience and Sensory Organs
University of Bari “Aldo Moro”


Current Pharmaceutical Biotechnology 18-8


Current Biotechnology 6-4


Current Neuropharmacology 15-8


Current Cancer Therapy Reviews 13-2


Current Pharmaceutical Design 23-29


Mini-Reviews in Organic Chemistry 14-6


Current Organic Chemistry 21-22


Current Medical Imaging Reviews 13-4


Current Proteomics 14-4


Endocrine, Metabolic & Immune Disorders – Drug Targets 17-4




Archana Chaudhary

Contributed Article: “Immunomodulatory Role Of Arsenic On Regulatory T Cells



%d bloggers like this: